Patents by Inventor Jeremy Hatem TCHAICHA

Jeremy Hatem TCHAICHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER
    Publication number: 20240131069
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
    Publication number: 20220332780
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (EL15) payloads, as well as compositions and methods of use thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: October 20, 2022
    Inventors: Kutlu Goksu ELPEK, Dhruv Kam SETHI, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER
  • ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER
    Publication number: 20220133801
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • CA2 compositions and methods for tunable regulation
    Patent number: 11058725
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: July 13, 2021
    Assignee: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
  • CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
    Publication number: 20210069248
    Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 11, 2021
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Kutlu Goksu ELPEK, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER